SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Peritoneal Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Peritoneal Cancer. According to …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Solid Tumor. According to …
Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Epidermolysis Bullosa. According to GlobalData, …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hepatocellular Carcinoma. According to …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Small-Cell Lung Cancer. According …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma. According to …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Melanoma: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Melanoma. According to GlobalData, …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Head And Neck Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Head And Neck Cancer. …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Cervical Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Cervical Cancer. According to …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Ovarian Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer. According to …
(Dexborneol + edaravone) by Neurodawn Pharmaceutical for Acute Ischemic Stroke: Likelihood of Approval
(Dexborneol + edaravone) is under clinical development by Neurodawn Pharmaceutical and currently in Phase I for Acute Ischemic Stroke. According …
Weekly insulin analogues approaching approval could herald change
Upcoming weekly insulin candidates can reduce the injection burden on patients with diabetes and ease the load on healthcare resources, …
“Lack of harmonisation in Europe” hindering gene therapy growth
Amid a US regulatory landscape promoting collaboration in cell and gene therapy development, SpliceBio’s CEO Miquel Vila-Perelló has questioned why …